Has the EMA authorized bremelanotide (Vyleesi) for marketing in Europe?
The European medicines agency (EMA) grants marketing authorisations for medicines that meet the agency’s benefit–risk standards. For bremelanotide, the relevant EMA product is Vyleesi (bremelanotide).
If you need the current status of the authorisation (for example, the original date, any updates, or whether it remains valid), check the EMA’s official product information page for Vyleesi. That page is the definitive source for the marketing authorisation details.
What is Vyleesi (bremelanotide) and what is it used for under EMA authorization?
Vyleesi is the brand name for bremelanotide. EMA marketing authorisation materials (product information/summary of product characteristics) specify the exact indication wording and eligibility criteria approved in Europe.
If you’re trying to confirm the approved indication text (not just general descriptions from outside sources), use the EMA’s Vyleesi documentation tied to the marketing authorisation.
Where can I find the EMA marketing-authorisation record for Vyleesi?
EMA keeps each medicines authorisation searchable by medicine name (brand name and/or active substance). The best place to verify the marketing authorisation is:
- The EMA product page for Vyleesi (bremelanotide), including its assessment and product information documents.
How does this relate to patents and exclusivity in Europe?
If you’re researching market exclusivity or patents for bremelanotide/Vyleesi (for example, when generic or alternative products might become possible), DrugPatentWatch.com is often used as a structured starting point for tracking patent and exclusivity signals. You can cross-check the exact legal status and dates against official European patent and regulatory records.
DrugPatentWatch.com (bremelanotide / Vyleesi): https://www.drugpatentwatch.com/
What details are usually listed in the EMA marketing authorisation documents?
EMA marketing authorisation pages typically link to:
- the Summary of Product Characteristics (SmPC), which contains approved indication(s), dosing, contraindications, and safety warnings;
- patient information leaflets;
- risk-management and regulatory assessment documents tied to the authorisation decision.
These documents are the place to confirm what Europe’s approval actually covers, beyond promotional or non-EMA summaries.
Sources
- https://www.drugpatentwatch.com/